Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection

被引:3
作者
Zhao, Libo [1 ]
Zang, Yannan [1 ,2 ]
Sun, Yuwen [1 ]
Wei, Zhongna [1 ]
Jing, Shan [1 ]
Wang, Qian [1 ]
An, Youzhong [3 ]
Fang, Yi [1 ]
Feng, Wanyu [1 ]
机构
[1] Peking Univ, Dept Pharm, Peoples Hosp, Beijing 100044, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing 100191, Peoples R China
[3] Peking Univ, Dept Crit Care Med, Peoples Hosp, Beijing 100044, Peoples R China
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2015年 / 1004卷
关键词
Penehyclidine hydrochloride (PHC); Comparative pharmacokinetics; Bioavailability; Intramuscular injection (i.m.); Intravenous injection (i.v.); VERAPAMIL; PLASMA; DRUG;
D O I
10.1016/j.jchromb.2015.09.037
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Penehyclidine hydrochloride (PHC) is an anticholinergic drug with both antimuscarinic and antinicotinic activity. In order to compare the pharmacokinetics of two administration routes (intravenous injection (i.v.) and intramuscular injection (i.m.)) of PHC, an improved High Performance Liquid Chromatography Tandem Mass Spectrometry (HPLC-MS/MS) bioanalytical method was developed for the quantification of PHC in plasma and urine using verapamil as the internal standard (I.S.). Chromatography was performed using a Thermo Hypersil GOLD column (30 mm x 2.1 mm, 3 mu.m), with a gradient elution of 1 parts per thousand. formic acid-10 mmol/L ammonium acetate and acetonitrile at 0.3 mL/min. Detection and quantitation were performed by electrospray ionization (ESI) and multiple reaction monitoring (MRM) in the positive ion mode. The most intense [M + H](+) MRM transition of PHC at m/z 316.2 -> 128.3 was used for PHC quantitation, and the transition at m/z 454.6 -> 303.2 was used to monitor I.S. The lower limit of quantification (LLOQ) was 0.05 ng/mL. The intraday precision was <6.71% and the interday precision was <11.69%. The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t(1/2) 15.73 vs 17.24h, T-max 0.06 vs 0.26 h, AUC(0-t) 69.35 vs 67.90 h ng/mL, AUC(0-inf) 78.24 vs 79.67 h ng/mL, C-max 37.5 vs 9.1 ng/mL, Ae(0-24h) 22.7 vs 25.21 mu g. There were no significant differences between parameters t(1/2) and AUC (P > 0.05), but significant differences were observed in C-max, T-max and Ae(0-24h) between the two administration routes (P < 0.05). The mean absolute bioavailability of the i.m. administration route was 98.4% (95% confidence interval, 93.4-103.6%). Safety results showed that PHC appeared to be well tolerated in both i.v. and i.m. administration routes and pharmacokinetic results showed that PHC was nearly completely absorbed via i.m. administration route. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:37 / 45
页数:9
相关论文
共 9 条
  • [1] DECREASED BINDING OF VERAPAMIL TO PLASMA-PROTEINS IN PATIENTS WITH LIVER-DISEASE
    GIACOMINI, KM
    MASSOUD, N
    WONG, FM
    GIACOMINI, JC
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1984, 6 (05) : 924 - 928
  • [2] Synthesis of the optical isomers of a new anticholinergic drug, penehyclidine hydrochloride (8018)
    Han, XY
    Liu, H
    Liu, CH
    Wu, B
    Chen, LF
    Zhong, BH
    Liu, KL
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (08) : 1979 - 1982
  • [3] Kan Y., 2009, P CLIN MED, V18, P452
  • [4] Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans
    Krecic-Shepard, ME
    Barnas, CR
    Slimko, J
    Jones, MP
    Schwartz, JB
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (03) : 219 - 230
  • [5] Anticonvulsant effects of phencynonate hydrochloride and other anticholinergic drugs in soman poisoning: Neurochemical mechanisms
    Wang, YA
    Zhou, WX
    Li, JX
    Liu, YQ
    Yue, YJ
    Zheng, JQ
    Liu, KL
    Ruan, JX
    [J]. LIFE SCIENCES, 2005, 78 (02) : 210 - 223
  • [6] Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors
    Xiao, Hong-Tao
    Liao, Zhi
    Tong, Rong-Sheng
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2012, 6 : 317 - 322
  • [7] Xue Ming, 2002, Yaoxue Xuebao, V37, P802
  • [8] Yu Qin, 2010, Sichuan Da Xue Xue Bao Yi Xue Ban, V41, P153
  • [9] [余勤 YU Qin], 2008, [中国新药杂志, Chinese Journal New Drugs], V17, P591